targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02177695 | Active, not recruiting | 2 | 2014-07-01 | null | null | null | null | Phase II+ | 85,899,347,438 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002949 | Completed | 1 | 1996-07-01 | null | null | null | null | null | 283,467,841,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT02845050 | Withdrawn | 1 | 2016-07-01 | Withdrawn | stopped | null | null | null | 300,647,711,926 | No participants found | Phase 1/Phase 2 | 31/07/2016 | Withdrawn | 13/02/2018 | 31/07/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00585689 | Completed | 2 | 2007-12-01 | null | null | null | null | Phase II+ | 335,007,450,344 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00583349 | Unknown status | 1 | 2007-12-01 | null | null | null | null | null | 429,496,730,724 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003133 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 463,856,469,994 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005644 | Completed | 2 | 2000-05-01 | null | null | null | null | Phase II+ | 515,396,076,988 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |